Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
06:30am, Wednesday, 04'th Jan 2023
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the Company's President and CEO Gilmore O'Neill,
Editas Medicine, Inc. (EDIT) EDIT-301 Clinical Update 2022 - (Transcript)
12:11pm, Tuesday, 06'th Dec 2022
Editas Medicine, Inc. (NASDAQ:EDIT ) EDIT-301 Clinical Update Call December 6, 2022 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Gilmore O'Neill - President and Chief Executive Of
2 Beaten-Down Stocks to Watch Closely Next Year
09:53am, Tuesday, 06'th Dec 2022
These biotechs could skyrocket in 2023, but only if they can execute their plans.
Editas shares jump 9% on positive news from sickle-cell study
08:00am, Tuesday, 06'th Dec 2022
Shares of Editas Medicine Inc. EDIT, -4.10% rallied 9.3% in premarket trading on Tuesday after the company said in a news release that it had positive results from the first two patients enrolled in a
Why Shares of Editas Medicine Dropped 15.5% in November
04:56pm, Monday, 05'th Dec 2022
The biotech's shares plummeted after it paused a key clinical trial.
Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why
02:17pm, Monday, 28'th Nov 2022
Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase I/II BRILLIANCE study on EDIT-101, treating Leber congenital amaurosis type 10.
Where Will Editas Medicine Be in 1 Year?
08:30am, Sunday, 20'th Nov 2022
The company could continue lagging the market for a while.
Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus
02:18pm, Thursday, 03'rd Nov 2022
Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.
Editas Medicine, Inc. (EDIT) Q3 2022 Earnings Call Transcript
10:50am, Wednesday, 02'nd Nov 2022
Editas Medicine, Inc. (NASDAQ:EDIT ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Gilmore O'Neill - Chief Executive Officer Baiso
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates
09:02am, Wednesday, 02'nd Nov 2022
Editas (EDIT) delivered earnings and revenue surprises of 6.90% and 99.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
06:30am, Wednesday, 26'th Oct 2022
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on W
Editas Medicine, Inc. (EDIT) Management Presents at Morgan Stanley 20th Annual Global Healthcare Conference Call Transcript
02:53pm, Monday, 12'th Sep 2022
Editas Medicine, Inc. (NASDAQ:EDIT ) Morgan Stanley 20th Annual Global Healthcare Conference Call September 12, 2022 10:30 AM ET Company Participants Gilmore O'Neill - President and Chief Executive Of
Editas Medicine, Inc. (EDIT) Presents at 2022 Wells Fargo Healthcare Conference (Transcript)
05:57pm, Wednesday, 07'th Sep 2022
Editas Medicine, Inc. (NASDAQ:EDIT ) 2022 Wells Fargo Healthcare Conference September 7, 2022 1:55 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Mark Shearman - Chief Scientific
Editas Medicine to Participate in Upcoming Investor Conferences
06:30am, Thursday, 01'st Sep 2022
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming
Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies
06:24am, Tuesday, 23'rd Aug 2022
Results from phase 1/2 BRILLIANCE study using EDIT-101 (Cas9 nuclease) for the treatment of patients with Leber Congenital Amaurosis 10 expected 2nd half of 2022. Results from the phase 1/2 RUBY study
